AVBP
Income statement / Annual
Last year (2023), ArriVent BioPharma, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, ArriVent BioPharma, Inc. Common Stock's net income was -$69.33 M.
See ArriVent BioPharma, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$64.88 M
|
$30.43 M
|
$6.43 M
|
| General & Administrative Expenses |
$9.71 M
|
$6.47 M
|
$3.02 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
-$753,999.00
|
| Selling, General & Administrative Expenses |
$9.71 M
|
$6.47 M
|
$2.26 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$74.59 M
|
$36.91 M
|
$8.70 M
|
| Cost And Expenses |
$74.59 M
|
$36.91 M
|
$8.70 M
|
| Interest Income |
$5.26 M
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$36.91 M
|
$11.59 M
|
| EBITDA |
-$74.59 M |
-$36.91 M |
-$51.61 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$5.26 M
|
$0.00
|
-$60.11 M
|
| Income Before Tax |
-$69.33 M
|
-$36.91 M
|
-$51.61 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$36.91 M
|
-$11.59 M
|
| Net Income |
-$69.33 M
|
-$36.91 M
|
-$51.61 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-2.17 |
-1.1 |
-1.54 |
| EPS Diluted |
-2.17 |
-1.1 |
-1.54 |
| Weighted Average Shares Out |
$31.96 M
|
$33.49 M
|
$33.49 M
|
| Weighted Average Shares Out Diluted |
$31.96 M
|
$33.49 M
|
$33.49 M
|
| Link |
|
|
|
